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Abstract
Atrial fibrillation (AF), the most prevalent rhythm disorder in clinical practice, is currently significantly contributing 
to morbidity and mortality of the ageing population. In the past decades, a tremendous amount of research resulted in 
valuable insights into AF pathophysiology, with a primary focus on atrial remodeling. Defined as a persistent change 
in atrial function and structure, remodeling has the intrinsic properties to enhance the probability of focal (ectopic) 
and/or re-entrant pursuits, thus supporting AF persistence. The hallmark of structural remodeling is represented by 
atrial fibrosis, a multifactorial process involving an interaction between neurohormonal and cellular mediators. This 
paper provides a brief summary of the recent knowledge with respect to electrical and structural remodeling and 
novel insights into the pathogenesis of atrial fibrosis. Since current drug options for AF treatment are far from being 
optimal we also discuss the therapeutic principles and current alternatives for counteracting atrial fibrosis, and thus 
preventing arrhythmia recurrence.
Atrial Remodeling in Permanent Atrial Fibrillation: Mechanisms and 
Pharmacological Implications
Danina M Muntean1, Zsófia Kohajda2,3, Tamás Fazekas4 and Norbert Jost1-3*
1Department of Pathophysiology, University of Medicine and Pharmacy, Timisoara, Romania
2Division of Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged, Hungary
3Department of Pharmacology & Pharmacotherapy, Faculty of Medicine, University of Szeged, Hungary
4First Department of Internal Medicine, Faculty of Medicine, University of Szeged, Hungary
Keywords: Atrial fibrillation; Atrial electrical remodelling; Atrial 
fibrosis; Antifibrillatory drugs
Introduction
Atrial fibrillation (AF) has a prevalence of 1.5-2% in general 
population and represents a major cause of morbidity and a socio-
economic burden that is expected to grow worth in coming decades 
mainly in the developed countries. The arrhythmia is associated with 
high risk of stroke due to thromboembolism, of congestive heart failure 
and, also accounts for the highest rate of hospitalization among all types 
of arrhythmia, especially with advancing age [1].
AF is initiated when an atrial ectopic beat encounters during 
propagation an anatomical and/or functional obstacle and triggers 
the re-entry of the excitation wavefront. The classic mechanisms 
underlying the ectopic activity are represented by: (i) increased 
automaticity and (ii) triggered activity expressed as early (EAD) or 
delayed afterdepolarizations (DAD). It is nowadays proven that atrial 
cardiomyocytes in the pulmonary sleeve veins may present increased 
automaticity/pacemaker activity; they represent ectopic foci responsible 
for the initiation of single or multiple reentry circuits [2,3]. There are 
2 main theories that explain the persistence of AF, namely: (i) the 
‘leading circle’ theory implying the existence of single/multiple reentry 
circuits [2] and, more recently, (ii) the cardiac electric rotors theory [4]. 
Figure 1 depicts the pathophysiological changes that are involved in the 
initiation of AF.
Persistent or recurrent AF is constantly associated with the 
phenomenon of atrial remodeling characterized by electrical 
and structural changes of cardiomyocytes that are responsible 
for arrhythmia self-perpetuation and resistance to sinus rhythm 
conversion. The changes that contribute to atrial remodeling in AF 
include: (i) alterations of ion channels, gap-junctions, and extracellular 
matrix and, (ii) neurohumoral dysregulation, in particular of the renin-
angiotensin-aldosterone system (RAAS) and the autonomic nervous 
system.
The paper briefly presents novel insights into the pathophysiology 
of atrial remodeling with particular emphasis on atrial fibrosis. The 
currently available therapeutic options and strategies for developing 
novel pharmacologic agents capable to prevent/treat atrial remodelling 
are also discussed.
Mechanisms of Atrial Remodeling
Remodeling in AF lies at the very core of the progressive nature 
of the arrhythmia. During the past decades the phenomenon has been 
thoroughly characterized at cellular level with respect of three major 
components: electrical, contractile and structural remodeling that 
synergistically contributes to the generation of the vulnerable substrate 
[5].
Electrical remodeling is due to alteration of several ion channels with 
the subsequent shortening of the action potential (AP) and membrane 
hyperpolarization [6]. The changes are due to the downregulation of 
the plateau currents and upregulation of several repolarizing currents 
(Figure 2). In this respect, three major changes have been described in 
the past decade to underlie the AP triangularization: (i) downregulation 
of inward current ICa,L, (ii) upregulation of the inward rectifier current 
IK1, and (iii) activation of IK,Ach, respectively [7-10]. 
Electrical remodeling (shortening of the atrial refractoriness) 
is reversible after the sinus rhythm restoration; however, with AF 
persistence, calcium overload is the main intracellular signal responsible 
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calcium during AF progression and after its termination, respectively. 
Accordingly, in the case of the former three stages occur: (i) Ca2+ 
overload, (ii) remodeling, and (iii) steady state, whereas during the 
latter, ‘recovery’ of calcium concentration also occurs in three steps: (i) 
calcium unloading, (ii) reverse remodeling and (iii) full recovery. In 
this respect, it is important to mention that the previously mentioned 
stage of remodeling is apparently associated with ‘Ca2+ silencing’ [14]. 
These observations are relevant for both the development of novel 
mechanism-based therapeutics agents acting as calcium ‘stabilizers’ and 
the timing of their administration [15]. 
Another direct consequence of altered calcium handling, referred 
as contractile remodeling, consists in loss of atrial contractility with 
subsequent increase in compliance and, finally, atrial dilation. One of 
the important consequences of atrial dilation has been classically related 
to the risk of atrial thrombosis even after sinus rhythm restoration [7]. 
However, this paradigm has been recently challenged by the group 
of Stanley Nattel who was not able to demonstrate the prothombotic 
for further promoting reentry [10]. Indeed, high Ca2+ concentration 
will bind calmodulin with the subsequent activation of calcineurin 
and trigger the signalling events responsible for perpetuation of the 
AP shortening and hyperpolarization, namely the increase in the 
previously mentioned potassium currents [10]. However, it is not clear 
whether electrical remodeling per se is relevant in clinical settings, since 
in a recent study no significant differences were found in the change in 
electrophysiological properties over 2 years between patients with and 
those without atrial tachyarrhythmias [11].
Calcium overload of atrial cardiomyocytes also lies at the origin of 
the Ca2+ sparks via the increased activation of the ryanodine receptors 
at the sarcoplasmic reticulum, an event that most probably contributes 
to the contractile remodelling [12]. Interestingly, in heart failure, one of 
the most frequent pathologic condition that predispose to AF, changes 
in intracellular Ca2+ handling preceding the onset of AF are different 
from those developing after the onset of AF [13]. Moreover, a recent 
report suggests a different dynamic for the alterations in intracellular 
Figure 1: Panel (A) Principal factors involved in inducing and maintaining AF. Panel (B) AF is started by an extrasystole originated from a pacemaker 
region (commonly left upper pulmonary vein), initiated by atrial tachycardia remodeling (ATR induced APD shortening). The electrical perpetuator may 
be a single/mother wave and/or multiple wave/circuit re-entry. The main re-entry initiating factors are: atrial ischaemia and inflammation. The principal 
factors of structural/morphological remodeling: atrial (micro)fibrosis and left atrial dilation. List of abbreviations: AF=atrial fibrillation; RA=right atrium; 
LA=left atrium; EAD=early afterdepolarization; DAD=delayed afterdepolarization; PVs=pulmonary veins; APD=action potential duration; RP=refractory 
period; WL=wavelength). Modified from Ref [8] with permission.
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effects of AF-associated remodeling in an elegant study performed in 
canines [16].
Chronic atrial stretch and geometric deformation are the major 
activators of the signalling pathways leading to cellular hypertrophy 
and diffuse and patchy interstitial fibrosis [17], collectively termed 
structural remodeling, the main mechanism responsible for the 
progression of AF. Structural remodeling refers to both the cellular 
and non-cellular components of the atrial tissue and results in local 
conduction heterogeneities that account for AF self-perpetuation. 
Predictably, structural remodeling will be less reversible as compared 
to the electrical one. However, it should be mentioned that structural 
remodeling is also the hallmark of heart failure and of other underlying 
chronic cardiac pathologies; therefore, the occurrence of AF is favoured 
in these settings. 
In the past few years, with the rapid evolution of research in the field 
of microRNA (miRNA), a class of small, non-coding RNA molecules 
that silence gene expression at the post-transcriptional level, a role of 
miRNA in both AF associated electrical and structural remodeling has 
been described. Thus, in the case of the former, downregulation of miR-
26 was associated with increased density of IK1, whereas upregulation 
of miR-328 elicited ICa,L reduction in both animal and human atrial 
samples [18]. As concerning the latter issue, Shan et al. [19] reported, 
in a dog model of AF induced by nicotine administration and rapid 
pacing, a profibrotic response characterized by significant upregulation 
of expression of TGF-beta1 and TGF-betaRII proteins together with 
a 60-70% reduction of the anti-fibrotic miR-133 and miR-590 levels. 
In the same line, knockdown of atrial miR-21 has been reported to 
suppress atrial fibrosis and duration of AF 8 weeks after experimental 
myocardial infarction in rats [20]. Recently, miR-499 was found to 
be significantly upregulated in atrial myocardium of 4 subjects with 
permanent AF, leading to the downregulation of the small-conductance 
calcium-activated potassium channel 3 (SK3) proteins [21]. Whether 
this finding might contribute to the electrical remodeling in AF remain 
to be established. In the same line, it has been recently reported that 
miR29 was significantly decreased in patients with chronic heart failure 
and atrial fibrillation; moreover, miR29b knockdown in canine atrial 
fibroblasts elicited an increase in colagen expression thus contributing 
to atrial fibrotic remodeling [22]. Therefore the authors concluded 
that miR29 may be used in the future as potetential biomarker and/or 
therapeutic target.
The past decade witnessed a huge resurgence of interest in the role of 
mitochondria in cardiovascular health and disease. In this line, a recent 
prospective study reported an association between pre-operative atrial 
mitochondria dysfunction and the occurrence of AF in patients with 
metabolic syndrome undergoing CABG surgery [23]. In permeabilized 
cardiac fibres, these authors demonstrated a decreased respiration of 
permeabilized fibres in the presence of pyruvate-malate and palmitoyl-
L-carnitine (but not of succinate) and an increased sensitivity to 
calcium overload. We have recently performed a similar study aimed 
at assessing the respiratory function in permeabilized fibres of human 
right atrial appendages harvested from patients with coronary heart 
disease vs. patients with valvular disease and preserved ejection fraction 
that underwent non-emergency cardiac surgery. Similarly to the 
previously mentioned data, we also found in coronary patients (but not 
in valvular ones) a significant decline for the oxidative phosphorylation 
capacity and respiratory control ratio for mitochondria energized with 
complex I (but not with complex II) substrates [24]. These observations 
are in the line with previous reports suggesting that treatments aimed 
at supporting cardiac mitochondria function might be able to mitigate 
electrical dysfunction in the heart [25].
Causes and Consequences of Atrial Fibrosis
In the past decade the contributing role of the structural remodeling 
(for example fibrosis) in initiating and maintaining and of AF has been 
extensively investigated, with a major emphasis on the occurrence of 
atrial fibrosis. 
Tissue fibrosis represents the common endpoint in diseased hearts 
from hypertensive, valvular, coronary, diabetic and failing patients. 
Figure 2: Major transmembrane ionic currents underlying atrial AP in sinus rhythm (SR) and in AF (ion channel remodeling). Left column presents ionic 
channel/current densities. Middle and right columns represent that AF induced alterations at the expression level current subunit forming proteins and 
genes, respectively. Pictograms show the course (magnitude and time duration) of the respective current. Magnitude and time course of the pictogram 
reflect approximately the real format proportions. Modified from Ref [9] with permission.
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In 2/3 of cases AF is secondary to a pre-existent organic heart disease 
that contributes to the development of the vulnerable substrate for AF, 
whereas lone AF occurs in 1/3 of patients. Nevertheless, there is both 
experimental and clinical evidence that AF itself is able to promote 
fibrosis [26]. However, the timing of AF appearance is equally important 
since, in a recent study, prognosis in patients who developed AF before 
or consecutively with heart failure was less severe as compared with 
those who firstly developed heart failure [27].
Atrial fibrosis in the setting of AF is the result of complex 
interplay among profibrotic signalling pathways, inflammation and 
oxidative stress, the first two contributors being extensively studied. 
Indeed, profibrotic signalling pathways have been recently described 
and include the: (i) RAA system with angiotensin II acting on AT-1 
receptors and aldosterone acting on the mineralocorticoid receptors, 
promoting both atrial and ventricular fibrosis, and the (ii) TGF-beta1 
that stimulates collagen production via the SMAD pathway. Also, AF 
has been associated with high levels of inflammatory serum biomarkers 
and a positive effect of anti-inflammatory agents [28]. However, in an 
important population based case-control study, the use of non-aspirin 
NSAIDs has been reported to increase the relative risk of AF or flutter 
[29]. Atrial fibrosis results in electrical dissociation between adjacent 
muscle bundles with discontinuous transverse conduction and also, 
between the epicardial layer and endocardial bundles leading to both 
focal and macro-reentry [30]. 
We will briefly mention some novel insights related to the role 
of oxidative stress in AF pathophysiology, since increased reactive 
oxygen species (ROS) production occurs with ageing as it does the AF 
prevalence. The major sources of ROS in the atria are: NADPH oxidases 
(NOX 1, 2 and 4), the electron transport chain (ETC), uncoupled 
NO synthase (NOS), and in some extent myeloperoxidase (MPO) 
[31,32]. Interestingly, the participation of ROS sources varies with the 
progression of the disease, an observation with important therapeutic 
implications. Thus, in both animals and humans, superoxide anion was 
reported to be NADPH oxidase (NOX2) dependent at 2 weeks of AF 
and NOS- and mitochondria-dependent after 6 months of AF [33]. 
These authors speculated that the early but transient increase of atrial 
NADPH oxidases may explain why statins (that inhibit NOX2) prevent 
postoperative AF but are less effective in the secondary prevention of 
the arrhythmia [33].
A second major source of superoxide anion which generates the 
highly reactive peroxynitrite is represented by NO synthases [34]. In a 
canine model of AF induced by seven days of tachypacing, induction of 
NOS isoform 2 (NOS2) has been reported [31]. 
Drugs or investigational 
compounds Effects Preclinical studies Clinical studies
Improvement of current 
antiarrhythmic agents
Azimilide (FDA approval)
Primarily IKr and IKs blocker but 
additionally blocks ICaL and INa (multi-
channel blocker)
Several in vitro and in vivo animal 
models [38-41]
ALIVE, A-STAR, A-COMET 
I and II Studies [42,43]
HMR-1556 Highly selective IKs blocker
Several in vitro and in vivo animal 
models [44,45] Not
AZD7009
Primarily IKr and INa blocker, but 
additionally blocks Ito, IKur and IKs 
(multi-channel blocker)
Several in vitro and in vivo animal 
models [46-48]
Small centre clinical trial 
[49,50]
Dronedarone (FDA approval) Amiodarone like multichannel blocker (INa, ICa, IKr blocker)
Several in vitro and in vivo animal 
models [51-53]
ADONIS, ATHENA, 
EURIDIS etc. [54-58]
Tedisamil Multichannel blocker (INa, Ito, IKr, IKs, IKATP, blocker)
Several in vitro and in vivo animal 
models [60-62]
Small centre clinical trial 
[63,64]
Atrial selective 
therapeutic agents
AVE0118 Primarily IKur, Ito and IK,ACh blocker
Several in vitro and in vivo animal 
models [67-72] not
XEN-D0101 Highly selective IKur blocker
Several in vitro and in vivo animal 
models [73,74]
Small centre clinical trial 
[75]
DP01 Highly selective IKur blocker
Several in vitro and in vivo animal 
models [76,77] Not
Vernakalant
Primarily IKr and INa blocker, but 
additionally blocks Ito, INa, IKr and IKs 
(multichannel blocker) 
Several in vitro and in vivo animal 
models [78-80] AVRO [81,82]
Ranolazine (FDA approval)
Primarily INaf and INaL, and IKr blocker, 
but additionally blocks ICaL and IKs 
(multichannel blocker)
Several in vitro and in vivo animal 
models [85-88] MERLIN-TIMI [89]
NIP-142, NIP-152 Highly selective IK,ACh blockers
Several in vitro and in vivo animal 
models [93,94] not
tertiapin Q Highly selective IK,ACh blocker
Several in vitro and in vivo animal 
models [9,90,96,97] not
NCX modulators
KB-R7943
Initially developed as selective NCX 
blocker, but additionally blocks Ito, IK, 
IK1, INa, and ICaL
Several in vitro and in vivo animal 
models not
SEA-0400 Selective NCX blocker, but additionally blocks ICaL
Several in vitro and in vivo animal 
models not
ORM-10103 Highly selective and potent NCX blocker in vitro animal model [104] not
Gap-junction therapy
Rotigaptide Selective gap junction closer peptide Several in vitro and in vivo animal models [108,109] not
GAP-134 Selective gap junction closer peptide Several in vitro and in vivo animal models [110,111] not
Table 1: New drugs and investigational compounds developed for treating AF.
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A third important source of ROS is the ETC at the inner 
mitochondrial membrane. In a mouse model of cardiac renin-
angiotensin system activation (ACE8/8) presenting with a high rate 
of spontaneous ventricular tachycardia and reduction in connexin-43 
level, administration of a mitochondrial antioxidant (MitoTempo) 
significantly decreased ventricular tachycardia inducibility, diminished 
elevated mitochondrial ROS, and increased connexin-43 and 
conduction at the gap junctions [35].
As for MPO, when released from polymorphs, it generates 
hypochlorous acid that further contributes to the tissue fibrosis via the 
activation of matrix metalloproteinases [31]. 
ROS elevation aggravates AF evolution by affecting ionic currents, 
gap junctions, inflammation and fibrosis (see [32] for a recent review); 
therefore, targeting oxidative stress is nowadays regarded as a potential 
“upstream therapy” [34], especially when considering the fact that 
many of the current pharmacologic therapies lack atrial specificity 
or/and are proarrhythmic. Indeed, as recently suggested, primary 
prevention of AF and postoperative AF may benefit from NADPH 
oxidases inhibitors, whereas in persistent AF mitochondria-targeted 
antioxidants may prove to be most effective [32]. 
Modalities for Prevention and Therapy of Atrial 
Remodeling 
Restoration of sinus rhythm versus rate control 
The rhythm control is the optimal therapeutic option and intervention 
to supress atrial fibrillation, i.e. to re-establish the normal sinus rhythm 
(SR). The rate control can be reached by several therapeutic approaches 
including to prolong atrioventricular nodal refractoriness and/or to 
slow of AV node conduction. These can be assessed by application 
of various types and classes of antiarrhythmic drugs from which we 
highlight especially the β-blockers, the Ca2+-channel blockers or the 
golden standard, the amiodarone [36]. It was demonstrated that ectopic 
 
Figure 3: The chemical structures of the presented specific, multiple, atrial selective ion channel blocker drugs and of the newly developed gap-
junction modulator antiarrhythmic peptides.
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triggers originating from pulmonary veins are sources of extrasystoles 
and, consequently, of AF. Eliminating the excitability of these ectopic 
triggers can terminate AF and, hence, provide rhythm control. This goal 
can be reached by several classical antiarrhythmic drugs which include 
especially the Na+ channel blockers or by multiple ion channel blockers 
(for example amiodarone). Based on the commonly accepted wavelet 
concept [2], short effective refractory periods and slowed conduction 
will enhance the probability of inducing re-entries. According to this 
theory, by counteracting either of them the conduction in the respective 
tissue will be enhanced (consequently that re-entrant wavefront will 
find the tissue still in refractory status).
Novel pharmacological agents and investigational compounds 
surmounting AF
The palette of currently existing antiarrhythmic agents for the 
treatment of AF are in principle far from being ideal, since, many of them 
have serious problems regarding not only their efficacy but also safety 
concerns. In general, all antiarrhythmic drugs combating ventricular 
arrhythmias may successfully suppress AF by lengthening atrial ERP 
and by of slowing atrial tissue conduction, but it is expected that their 
atrial selectivity to minimize ventricular proarrhythmic effects. This 
was referred as the ‘atrial selective drug concept’, which means these 
drugs are expected to target currents existing in the atria but not or 
only minimal the ones present in the ventricles. In addition these drugs 
must lack cardiac or extra cardiac organ toxicity and should be tolerable 
in patients having heart complications as for example coronary artery 
disease. 
There are several possibilities to design drugs for combating AF. 
The novel compounds can block: (i) specific or multiple ion channels, 
(ii) preferably in an atrial-selective manner, (iii) they can be directed 
at non-ion channel targets including upstream inflammatory or 
infiltrative processes or (iv) they may influence gap-junctions (the 
latter being considered the most modern pharmacological therapeutic 
approach of AF). We will briefly address further all these issues. At the 
end of this section Table 1 summarizes again all important data of the 
presented drugs. 
Drugs with specific and multiple ion channel blocking effects
The principal target for these drugs is to lengthen repolarization 
(i.e., class III compounds). During last two decades there were reported 
several novel compounds or investigational drugs; however, majority 
of them have been abandoned, because of the risk of ventricular 
proarrhythmic potency, especially of inducing Torsades de Pointes type 
tachyarrhythmias.
Selective IKs blockers
Azimilide (Procter & Gamble, specific IKr and IKs blocker, Figure 
3). The drug was designed based on an elegant developing idea from 
the mid-nineties (so called Sanguinetti’s hypothesis [37]). Accordingly, 
it was presumed that IKs blockers would be free of reverse rate-
dependency. However, the data showed that azimilide blocked not only 
IKs but IKr as well. Based on these results it was expected to be specifically 
effective during tachycardia which commonly associates with AF. Some 
reports showed that azimilide, like amiodarone, possesses calcium and 
use-dependent sodium channel blocking effects [38,39]. However, we 
must emphasize that after some encouraging studies in AF [40,41], the 
initial optimism disappeared and the modest results of several studies 
(e.g., the ALIVE study) ended up with the conclusion that azimilide will 
never become a powerful tool for treating AF [42,43]. 
HMR-1556 (IKs blocker, Figure 3). HMR-1556 is a pure IKs selective 
blocker and was designed based on the Sanguinetti’s hypothesis [37], 
which turned the attention of the pharmaceutical industry to IKs blockers. 
HMR1556 is the first powerful and highly selective IKs blocker that was 
tested as novel antiarrhythmic drug, and the results demonstrated that 
indeed effectively blocks IKs, and only at at higher concentration also 
inhibits Ito, the sustained outward current Isus, and ICaL currents [44]. In 
a canine model of vagal AF, HMR1556 prolonged the atrial effective 
refractory period (AERP) and exerted a modest effect on the duration 
of induced AF only in the presence of intact β-adrenergic stimulation. 
However, we must emphasize that in the last years several reports made 
questionable the efficacy of IKs blockers, especially in certain conditions, 
such as the long QT syndrome 1 and in other circumstances where 
repolarization reserve is compromised [45].
AZD7009 (Astra Zeneca, IKr and INa blocker, Figure 3). The 
pharmacological profile of AZD7009 includes a combined block of 
IKr and rate-dependent block of INa at micromolar concentrations. 
In addition later studies revealed that, in higher concentrations, the 
compound blocked other repolarizing currents such as Ito, IKur and IKs 
[46,47]. In dog atria, AZD7009 concentration-dependently reduced 
Vmax and increased APD. In addition, the suppression of Vmax, but not 
APD prolongation, showed used frequency-dependence also [48]. New 
clinical trials demonstrated AZD7009 to be successful in SR conversion 
in persistent atrial fibrillation [49,50]. It is presumable that the latter 
effect is the result of the favourable ion channel blocker profile of the 
compound.
Amiodarone-like multichannel blockers
The undoubted success of amiodarone promoted the concept that a 
simultaneous blockade of several specific inward and outward currents 
may result in a more favourable electrophysiological profile than that 
obtained through the use of single channel blockers [51]. 
Dronedarone (Sanofi Aventis, Figure 3) is so far the most promising 
recently drug developed based on this idea. The originating point for 
designing the dronedarone molecule was amiodarone but without 
containing an iodine. It is generally accepted that the iodine molecule 
of amiodarone is responsible for the severe extra-cardiac (pulmonary, 
thyroid, hepatic and ocular) toxicity of amiodarone [51]. The in vitro 
electrophysiological results showed that dronedarone possesses quite 
similar acute and chronic electrophysiological effects as known to 
amiodarone [52,53]. In dog ventricular preparations, dronedarone 
indeed was multi-channel blocker. Accordingly the drug blocked ICa,L 
and IKr, and reduced the maximum upstroke velocity in a frequency-
dependent manner [51]. Based on these promising preclinical 
investigations dronedarone has been recommended for combating 
atrial arrhythmias, including in intensive clinical treatment. 
Two large trials, ADONIS and EURIDIS, also showed the 
superiority of dronedarone over placebo. Accordingly dronedarone 
did not significantly lengthen the QT interval and had very low 
ventricular proarrhythmic effects (lack of causing torsades de pointes 
[54,55] arrhythmias). Later ATHENA (phase III randomised trial) 
investigators reported also encouraging results, from which we should 
emphasize the prolonged time to first cardiovascular hospitalization 
or death from any cause (the primary endpoint) by 24% compared to 
placebo [56]. Despite of these positive reports, it should be emphasized 
that dronedarone is still far from being a new golden antiarrhythmic 
drug. Several clinical reports indicated that the antiarrhythmic 
potential of the starting molecule amiodarone remains net superior to 
that of dronedarone [57,58]. After the results of the ATHENA trial, the 
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Food and Drug Administration (FDA) in U.S. approved dronedarone 
as secondary endpoint for the prevention of hospitalizations due to 
recurrent AF. Based on this rather unusual approval label dronedarone 
is not allowed to be marketed in US as primary anti-AF agent [58]. 
Recently, the administration of dronedarone was accompanied by 
severe extra-cardiac side effects, from which we must stressed out 
some recent cases of near fatal liver toxicity making immediate liver 
transplantation necessary [59]. 
Tedisamil (Figure 3) was initially developed by Solvay Pharma-
Kali Chemie AG as an anti-ischemic and bradycardic drug. Originally 
was supposed to be a selective Ito blocker, but later studies revealed 
that tedisamil possesses multichannel blocker effects. Indeed, the 
drug blocks several cardiac K+ currents (Ito, IKur, IKr, IKs and IKATP) and 
produces a negative chronotropic effect by increasing gap junction 
conductance and conduction velocity. This later may be extremely 
useful by preventing the fast ventricular rates, which characterize the 
atria in the case of AF recurrence [60-62]. Tedisamil probable due to 
its “amiodarone-like” multichannel blocker properties, lacks in atrial 
tissue from reverse use-dependency effects. In spite of these apparent 
positive electrophysiological profile, preliminary clinical studies showed 
modest efficacy results and relatively high proarrhythmic risk (several 
documented cases of ventricular tachycardia), thereby tedisamil seems 
to unlikely to be beneficial in combating AF [63,64]. The drug has not 
received approval from FDA.
Atrial selective ion channel blocker drugs
The most promising and effective strategy in AF is the 
development of drugs known as “atrial selective drugs”, thus avoiding 
the proarrhythmic ventricular side effects. This concept exploits the 
differences between electrophysiological and expression patterns of ion 
channels between atrial and ventricular myocytes. 
Accordingly, the development of atrial specific ion channel blockers 
can be reached by designing compounds that affect (block or activate) 
atrial selective transmembrane currents. Atrial specific targets suitable 
for developing novel treatment include: (i) the ultra-rapid delayed 
rectified potassium current (IKur), (ii) the acetylcholine-sensitive inward 
rectifier potassium current (IK,ACh), (iii) the constitutively active IK,ACh 
(i.e., which are active without initial activation of acetylcholine or 
muscarinic receptors), and, (iv) gap-junction constituent connexins 
(connexion 40, Cx40). In the light of the current knowledge, the channels 
responsible for IKur and IK,ACh are exclusively or near exclusively present 
in atria and largely absent in ventricles, thereby they are perfect targets 
for atrial selective ion channel blocker (or atrial repolarization delaying 
agent, ARDA) drugs. In addition, there are other ion channels present 
both in atria and ventricles, but due to their specific kinetic properties, 
the selective modulation of them may produce larger effect in atria 
than in ventricles, consequently they also correspond to the atrial 
selective antiarrhythmic drug criteria. In particular, sodium channels 
responsible for fast INa current correspond to this concept.
IKur blockers
Firstly described by Wang et al. [65], the ultra-rapid component 
of the delayed rectifier current (IKur) is considered the typical atrial 
selective transmembrane current. Subsequently, the pharmaceutical 
industry has invested large efforts in developing selective IKur blockers 
as novel pharmacological agents for suppressing AF. Indeed, several 
new purportedly selectively IKur blocking compounds were developed 
and investigated in the last decade, from which the most investigated 
were AVE0118, ISQ-1, DPO-1, XEN-D101, vernakalant; AZD7009; 
NIP-141, NIP-142, acacetin, etc). Of note, some reports, such as the 
one by Wettwer et al. [66] questioned the effectiveness of IKur blockers.
AVE0118 (Figure 3) was developed by Sanofi-Aventis. The 
biphenyl derivative AVE0118 blocks IKur at micromolar concentrations 
as reported in native atrial myocytes and in Kv1.5 cloned transgenic 
systems as well. In addition at similar concentration range the drug 
presented blocking effects on Ito and IK,ACh currents as well [67,68]. 
AVE0118 shortened APD and ERP in atrial tissue originating from 
patients in SR, whereas it prolonged APD/ERP in AF patients 
[69]. Experimental studies in large animals (dogs and goats) have 
demonstrated the potency to prolong the atrial ERP and convert AF to 
SR. This property was associated with only little effect on ventricular 
refractoriness and QT interval and had no proarrhythmic side effect. 
The atrial refractoriness effect presented a regional heterogeneity since 
appeared to be more pronounced in the left atrium, than in the right 
one. In normal goat atria, AVE0118 lengthened rate-dependently atrial 
ERP. In experimentally instrumented permanent AF model, after 48 h 
of continuous AF, AVE0118 successfully prolonged the atrial ERP to 
the pre-remodelled level, and was able to prevent induction of AF in 
the majority of the experiments [70-72]. There are no clinical studies 
performed with AVE0118 and seems that its development has probably 
been stopped.
XEN-D0101 (chemical structure not disclosed) was developed 
by a small R&D company (Xention Ltd, UK). XEN-D0101 seems to 
be the only really highly selective Kv1.5 channel blocker that has been 
developed so far. Several reports showed that XEN-D0101 effectively and 
selectively blocked IKur channels, prolonged the atrial ERP and decreased 
the duration of AF in humans and dogs [73,74]. Clinical studies with 
this compound to maintain sinus rhythm after cardioversion in patients 
with persistent AF are under way and preliminary reports support its 
efficacy in combating atrial arrhythmias [75].
DPO-1 (Diphenylphosphine oxide, Figure 3). DPO-1 In isolated 
human atrial myocytes, DPO-1 rate-dependently blocks IKur at 
nanomolar concentrations. The drug blocks other currents as Ito only 
at micromolar concentrations. In human atrial tissue, DPO-1 induces 
plateau elevation and shortening (in SR) and prolongation (in AF) of 
APD. These effects were clearly atrial selective, since the compound 
had neutral effect in ventricular tissue preparations. The compound 
has been studied in non-human primates and supressed atrial flutter by 
increasing atrial ERP by 13-15% [76,77]. 
Vernakalant (RSD1235, Cardiome and Astellas, Figure 3) is the 
atrial selective drug in the most advanced phase of investigation; it 
has been recently approved by the FDA for intravenous conversion of 
AF [3,78]. Vernakalant effectively blocked IKur in a positive frequency-
dependent manner; however, in higher concentrations other currents 
including Ito, and INa were also blocked, so it may be referred as a 
multichannel blocker than a selective IKur (ARDA) blocker. The drug 
slowed conduction velocity within the atrium and prolonged the ERP 
recovery. Due to Na-channel properties, vernakalant possesses fast 
offset kinetics, thereby it is unlikely to cause conduction disturbances 
and proarrhythmia at low heart rates [79,80]. Recently, the AVRO 
study (phase III clinical study) demonstrated that vernakalant when 
compared to amiodarone, possesses superior efficacy for acute 
conversion of recent-onset AF [81,82]. 
Sodium channel blockers
According to the “modulated receptor hypothesis” it is known that 
fast sodium channel blocker (for example Class IA antiarrhythmics) 
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drugs displays preferential binding to open (activated) or closed 
(inactivated; resting) states of the Na+-channel [83]. Since fast sodium 
channel is highly expressed in ventricular tissue, it is not obviously to 
explain and understand the atrial selectivity properties of Na+ channel 
blockers. Based on the hypotheses formulated by Antzelevitch and 
co-workers we may assume that the atrial selectivity of INa blockers 
is probable due to two important diffences of the atrial tissue in 
comparison with the ventricles: (i) atrial tissue has a slightly more 
positive (depolarized) resting potential; (ii) a more negative potential for 
half-maximum inactivation of INa. Due to more depolarized membrane 
potential during diastole, unlike in ventricles, fewer Na+ channel will 
recover faster from inactivation in the atria; consequently INa blockers 
known to bind more preferentially to the inactivated channel state will 
exhibit larger Na+ channel blockade in the atria as compared to the 
ventricles [84].
Ranolazine (Figure 3) was initially developed as an antianginal 
drug, but was soon recognized also to successfully suppressing 
ventricular EADs and to reduce transmural dispersion of APD [85]. In 
vitro electrophysiological investigations revealed that ranolazine blocks 
primarily late INa but several other currents as IKr, IKs, and even possibly 
L-type calcium current (ICaL) [86].. Ranolazine was shown to shown 
to reduce ischemic intracellular sodium and calcium overload, and to 
effectively suppress triggered activity, such as EADs. These properties 
were associated with the late INa current inhibiting properties. In order 
to determine whether INaL blockade may be effective in suppressing 
arrhythmias, extensive investigations were performed in isolated canine 
single (ventricular myocytes) and multicellular (wedge) preparations 
[87]. Ranolazine reduced the transmural dispersion of repolarization, 
a known proarrhythmic substrate [84]. Recent experiments in canine 
isolated perfused atrial and ventricular preparations have suggested 
that ranolazine shows a stronger affinity to atrial sodium channels 
than that of ventricular ones [88]. However, we must emphasize that 
clinical studies showed only moderate results when testing the effect of 
ranolazine in counteracting AF [89]. 
Atrial acetylcholine-sensitive potassium current (IK,ACh) 
blockers
Blockade of an another atrial-selective current, the acetylcholine 
activated inward rectifier K+ current, IK,ACh, is expected to exert an useful 
effect in vagally induced atrial fibrillation. Since IK,ACh is also absent in 
ventricles, the IK.ACh blockers, similar to IKur blockers, are also real ARDAs. 
Numerous investigations reported that activation of IK,ACh by vagal 
stimulation will parallel shorten atrial ERP and increase the availability 
of the Na+ channel, thereby can create of re-entry substrate based on the 
dispersion of atrial repolarisation. At high frequencies characteristic to 
AF, these reentrys may create rotors, which consequently promote the 
increased duration of AF episodes [90]. Several investigations reported 
that vagal activity can contribute to the initiation of paroxysmal AF 
[91,92], thereby some authors proposed the hypothesis that blockade 
of parasympathetic activity may have beneficial effects and could help 
to maintain SR; therefore, selective IK,ACh blockade may be a promising 
atrial selective therapeutic strategy [90]. 
NIP-142 (Figure 3) and NIP-151 (chemical structures not disclosed). 
NIP-142 is a benzopyrane derivative compound, which was synthetized 
as highly selective blocker of IK,Ach. Accordingly with the hypothesis, 
investigational results demonstrated that NIP-142 could prevent the 
acetylcholine-induced, arrhythmogenic AP shortening [93]. The 
congener derivative NIP-151 seems to be even more potent and more 
selective compound than NIP-142. A recent investigation reported 
performed in dogs, NIP-151, in an atrial selective manner, significantly 
lengthened atrial ERP and prevented vagally- and aconitine induced 
AF [94]. 
Constitutively active IK,ACh channels (CI-IK,ACh)
Recently, it has been shown that in atrial tissue originating from 
patients in permanent AF, the IK,ACh channels are opened and active 
without direct ligand stimulation, i.e. they are constitutively active 
(CC_IKA,CH) [90,95]. In this study it was hypothesised that in long term 
chronic AF constitutively active IK,ACh current is one of main responsible 
for APD abbreviation and triangularization, thus making the atria 
susceptible for reentry based tachyarrhythmias [90]. A logic conclusion 
of this observation was that selective blockade of CC_IK,ACh current may 
have potent antiarrhythmic/antifibrillatory effects [93]. However, due to 
lack of selective CI-IK,ACh antagonists, direct control of this hypothesis is 
not possible yet. However, in a recent study, this hypothesis was at least 
questioned. Indeed, in a experimentally induced tachypaced dog model 
of permanent AF (ATR), we have revealed that the real magnitude of 
the outward repolarizing CI_IK,Ach does not seem to be large enough 
to substantially contribute to the atrial ERP shortening and thus to 
the APD shortening [9,96,97]. Therefore, in this study [9] we have 
proposed the following new concept: in normal in vivo physiological 
condition a “background” vagal stimulation is always present, thereby, 
consequently it is probable that a acetylcholine-dependent IK,ACh 
exists in atrial myocytes either in SR or AF. In permanent AF the CI-
IK,ACh can also be activated, and its effect will add to the vagally stimulated 
IKA,Ch, so the resulting net outward current may become large enough to 
contribute to the atrial ERP/APD shortening. Consequently, blockade 
of this combined basal IK,ACh and CC_IK,ACh current may prevent AF. 
Indeed, in a series of recent experiments we have clearly demonstrated 
the presence of CI-IK,ACh in atrial cardiomyocytes isolated from ATR 
dogs, near of a clear presence of cholinergic activated IK,ACh currents 
[9]. Selective blockade of combined IK,ACh current with low nanomolar 
concentrations of Tertiapin Q (Figure 3) successfully prevented 
experimentally induced AF in conscious ATR dogs [9,96,97]. However, 
further investigations are performed presently to test this hypothesis. 
NCX modulators
The Na+/Ca2+ exchanger current (NCX) exchanges one intracellular 
Ca2+ ion for three extracellular sodium ions. During rapid atrial rates 
caused by AF or pacing, the larger entrant intracellular sodium relative 
to calcium may cause the bidirectional exchanger to work in the 
reverse mode, consequently elevating the intracellular Ca2+ level and 
thus contributing to the shortening of the action potential. These may 
increase the incidence of DAD (elicited by NCX1 activity) that in turn 
can trigger AF. Therefore, it has been postulated that NCX blockers 
as useful antiarrhythmic drugs [98,99]. Lack of potent and selective 
NCX blockers made impossible to unequivocally prove this hypothesis 
so far. During last decade several NCX blockers were developed and 
investigated but to date no true potent and selective NCX blocker has 
been reported. 
KB-R7943 (Kanebo, Figure 3) preferentially inhibits the reverse 
mode of the NCX. Several studies revealed also that this effect was 
associated by a clear blocking potency on sodium, potassium and 
calcium channels (Ito, IK, IK1, INa, and ICaL). In anesthetized dogs, KB-
R7943 prevented atrial ERP shortening caused by pacing-induced AF 
[100,101], but obviously this effect cannot be associated strictly to NCX 
blocking properties of the drug. 
SEA0400 (Taisho Pharmaceutical, Figure 3) is another NCX 
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inhibitor which is more selective and potent than KB-R7943, and for 
several years this was the most investigated NCX blocker compound. 
It was reported that SEA0400 effectively blocks NCX in both forward 
and reverse mode at micromolar concentrations; however, the drug 
also effectively suppressed the L-type Ca current (ICaL) at comparable 
concentrations [102]. In a recent study in humans where SEA0400 has 
been applied as a tool to identify NCX current, it was reported that the 
NCX current is significantly upregulated in AF as compared to SR [103]. 
In spite of many published reports that showed that NCX blockade with 
SEA0400 may suppress ectopic automaticity in pulmonary veins, we 
must emphasize that these observations remains questionable due to 
the lack of trusted selective NCX blocking effect [99].
ORM-10103 (Orion Pharmaceutical, Figure 3) is a novel developed, 
and purportedly the most selective and highly potent NCX blocker. In a 
recent study it was reported that ORM-10103 significantly reduced both 
the inward and outward NCX currents at submicromolar concentration. 
The drug did not significantly change the main repolarisation K 
currents (Ito, IKr, IKs, IK1), the L-type Ca2+ current, the Na+/K+ pump or 
the maximum rate of depolarization (dV/dtmax), indicative of the fast 
inward Na+ current even at the high concentration of 10 µM ORM-
10103, suggesting that, indeed, this is the firstly reported highly selective 
NCX blocker [104]. The amplitude of pharmacologically induced early 
and delayed afterdepolarizations were significantly decreased by ORM-
10103 (3 and 10 μM) in a concentration-dependent manner [104]. 
Gap junctions modulators
Electrical and structural remodelling caused by permanent AF 
involves significant changes in junctions at the atrial intercalated discs. 
These may include fascia adherens, the desmosomes, and recently, 
the gap junction proteins (N-cadherin, desmoplakin, and connexins). 
Cardiac connexins present two major isoforms: one with the molecular 
weight of 40 and 43 kDa, respectively. Atrial myocardium and 
conduction system express particularly connexin 40, while connexin 
43 is also present in conductive tissue [105]. There are some studies 
reporting that acute ischemia may close the gap junctions and slow 
conduction velocity. Therefore, it has been suggested that specific gap 
junctions’ modulators that prevent closing of cardiac gap junctions may 
possess antiarrhythmic effect against AF [106,107]. 
Rotigaptide (GAP-486, ZP123, Figure 3) is the firstly reported 
substance developed for protecting against the closing of the gap 
junctions. Rotigaptide is a peptide developed by applying the original 
antiarrhythmic peptide structure, where the d-isomers have been 
substituted for l-isomers. In acute coronary artery occlusion, rotigaptide 
was shown to effectively attenuate the conduction velocity slowing and 
ventricular arrhythmogenesis, while being neutral in controls [108,109].
GAP 134 (Figure 3) was designed with the specific aim to reduce 
atrial conduction velocity [110]. However, in a recent investigation 
performed in the acute dog model of permanent AF the drug did not 
prove to have either strong antiarrhythmic or AP lengthening potential 
[110,111]. We may summarize that gap junction modulators may 
be indeed novel and potentially efficacious pharmacological targets 
against AF, but several investigations are required to establish their real 
potential.
Other possible ion channel targets for novel antiarrhythmic 
drugs
There are several attempts for targeting other ion channels such 
as the: two pore-domain potassium channels [K2P] [112], transient 
receptor channels [TRP] [113], mechanosensitive, stretch activated 
channels [114], calcium activated K+-channels [115] etc. Based on the 
information of several investigations in native (especially ventricular) 
and transgenic systems many of them may be useful targets for 
antiarrhythmic exploitation; however, until now there are no or very 
few promising results suggesting that modulators of these channels may 
provide beneficial effects in preventing AF. 
Non ion-channel blockers – upstream therapy of AF
In addition to the ion channel-based AF therapy, there is a rapid 
development of non ion-channel approaches, aimed at reducing or 
reversing structural remodeling, inflammation, and oxidative stress 
injury associated with AF. These approaches are collectively referred to 
as “upstream therapies” [116,117].
As previously mentioned several pathophysiological processes, 
such as inflammation and oxidative injury, promote structural 
remodeling, including fibroblast proliferation, accumulation and/or 
redistribution of collagen, chamber dilation, and hypertrophy that are 
associated to AF. Proarrhythmic actions of atrial structural remodeling 
are generally related to conduction disturbances, which promote re-
entrant arrhythmias. Several experimental and clinical studies have 
shown that the so-called “upstream therapy” drugs affecting structural 
remodeling, inflammation, and/or oxidative stress, such as angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers, and 
statins may reduce the occurrence of AF [118,119]; while in contrary, 
other studies questioned the efficacy of such therapies in AF [120]. 
However, we must emphasize that numerous clinical trials proved that 
the use of statins was significantly associated with a decreased risk of 
atrial fibrillation in patients with sinus rhythm. The highest benefit 
was seen for the prevention of postoperative atrial fibrillation and in 
secondary prevention of atrial fibrillation, with a high heterogeneity, 
explained by differences in statin types, patient populations and surgery 
types [121,122].
We must also emphasize that the contribution of inflammation and 
oxidative stress in the development of AF is still not fully understood 
and varies significantly among different AF pathologies [36,123,124].
Conclusions
The past decades witnessed an enormous amount of research aimed 
at deciphering the mechanisms underlying atrial remodeling in AF and 
developing methods to counteract it. Both ion channel and non ion-
channel therapeutic approaches are envisaged in order to improve the 
management of AF. A great deal of attention is currently paid to novel 
antiarrhythmic drugs that possess high affinity for atrial myocardium or 
target multiple ion channels. Whether the use of these antiarrhythmic 
agents will translate into improved prognosis of patients with AF 
remains to be confirmed in larger-scale prospective trials.
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